Table 1 Characteristics of the studied groups
| Â | Asthma | Controls |
|---|---|---|
n | 44 | 18 |
Men/women [ n ] | 19/25 | 11/7 |
Age [years] | 53 (21-77) | 41(20-71) |
Period of observation [months] | 62 (9-124) | n.a. |
FEV 1 [%] | 79 (37-113) | n.a. |
PEF [l/s] | 365 (223-610) | n.a. |
Exacerbations per year | 0.97 (0-3.31) | n.a. |
Episodes of acute infection per year | 0.49 (0-2.51) | n.a. |
Hospitalization for asthma per year | 0 (0-0.83) | n.a. |
Nocturnal dyspnoe per year | 0.36 (0-3.16) | n.a. |
ICS [μg per day] | 1258 (158-3289) | n.a. |
Oral GCS [mg per day] | 1.6 (0-10.6) | n.a. |
Oral GCS [days of use per year] | 76.4 (0-365) | n.a. |
Montelukast [mg per day] | 2.3 (0-10) | n.a. |
Zafirlukast [mg per day] | 0 (0-26.1) | n.a. |
Smokers [%] | 20.5 | 16.6 |
Atopy [%] | 63 | 0.0 |
GERD [%] | 2.6 | 0.0 |
Chronic rhinosinusitis [%] | 20.5 | 0.0 |
Aspirin intolerance [%] | 10.2 | 0.0 |
Allergic rhinitis [%] | 59 | 0.0 |